Cytosorbents Corp (NASDAQ:CTSO)‘s stock had its “buy” rating reaffirmed by Maxim Group in a research note issued on Thursday.
The analysts wrote, “Summary Cytosorbents highlights recent cases using CytoSorb to successfully treat HLH (hemophagocytic lymphohistiocytosis) and notes the relevance of these cases to cytokine release syndrome (CRS) in cancer immunotherapy patients. Cytosorbents has now treated 10 secondary HLH patients with CytoSorb, with 3 published case reports and others pending. This month in the Journal of Clinical Immunology, in a case report entitled, Rescue of Cytokine Storm Due to HLH by Hemoadsorption in a CTLA4-Deficient Patient”, Greil and colleagues report the use of CytoSorb in successfully treating a 50-year old man with secondary HLH due to Epstein Barr virus (EBV) infection and associated Hodgkin’s lymphoma, and complicated by CTLA-4 deficiency. CTLA-4 deficiency is a genetic disorder that eliminates a key regulatory control element of cellular immunity and predisposes patients to severe inflammation. This patient was initially admitted for recurrent fevers, and was subsequently found to have a high grade EBV infection that triggered HLH, with kidney failure (requiring dialysis), liver failure, respiratory failure (requiring mechanical ventilation), shock (requiring vasopressors), and high inflammatory cytokines and other biomarkers. Despite the use of conventional HLH therapy, including high dose steroids, etoposide, and rituximab due to EBV infection, the patient worsened with progressive multi-organ failure. At that time, treatment with CytoSorb was initiated, subsequently treating for 4 consecutive days, each day with a new cartridge.””
A number of other research analysts have also commented on CTSO. B. Riley restated a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents Corp in a research note on Saturday, March 11th. Aegis restated a “buy” rating on shares of Cytosorbents Corp in a research note on Tuesday, March 7th. Finally, HC Wainwright lifted their price objective on shares of Cytosorbents Corp from $11.50 to $13.00 and gave the company a “buy” rating in a research note on Monday, March 6th. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $15.65.
Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down 2.63% on Thursday, reaching $5.55. 83,967 shares of the company were exchanged. The stock has a 50 day moving average of $5.51 and a 200-day moving average of $5.60. The company’s market capitalization is $141.65 million. Cytosorbents Corp has a 52-week low of $3.87 and a 52-week high of $6.90.
Your IP Address:
An institutional investor recently raised its position in Cytosorbents Corp stock. Advisor Group Inc. raised its position in shares of Cytosorbents Corp (NASDAQ:CTSO) by 1.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 305,145 shares of the company’s stock after buying an additional 3,300 shares during the period. Advisor Group Inc. owned about 1.20% of Cytosorbents Corp worth $1,953,000 at the end of the most recent reporting period. 6.07% of the stock is owned by institutional investors and hedge funds.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.